The natural history of clinically complete responders to neoadjuvant chemotherapy for urothelial carcinoma of the bladder.
Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York. Electronic address: [email protected]
Department of Urology, Herbert Irving Cancer Center, Columbia University Medical Center, New York, New York.
- Published Article
The Journal of urology
- Publication Date
Sep 01, 2014
With proper counseling and identification of treatment goals patients with cT0 after neoadjuvant chemotherapy for muscle invasive bladder cancer may have the option to retain the bladder with durable survival. Larger studies are needed to identify possible predictors of response on the clinical, pathological and molecular levels.
Report this publication
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 06/09/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/24657802